ProQR Therapeutics (PRQR) Lifted to Hold at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a sell rating to a hold rating in a research note issued to investors on Tuesday.

PRQR has been the subject of several other reports. Royal Bank of Canada initiated coverage on shares of ProQR Therapeutics in a report on Wednesday, December 19th. They issued an outperform rating for the company. Cantor Fitzgerald set a $40.00 price objective on shares of ProQR Therapeutics and gave the company a buy rating in a report on Tuesday, January 29th. Zacks Investment Research upgraded shares of ProQR Therapeutics from a hold rating to a strong-buy rating and set a $20.00 price objective for the company in a report on Wednesday, January 9th. Citigroup initiated coverage on shares of ProQR Therapeutics in a report on Thursday, November 15th. They issued a buy rating and a $32.00 price objective for the company. Finally, HC Wainwright reiterated a buy rating and issued a $20.00 price objective on shares of ProQR Therapeutics in a report on Thursday, February 28th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $28.67.

NASDAQ PRQR opened at $15.03 on Tuesday. ProQR Therapeutics has a 52 week low of $2.90 and a 52 week high of $24.00. The company has a quick ratio of 11.39, a current ratio of 13.28 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $581.96 million, a price-to-earnings ratio of -11.65 and a beta of 0.63.

A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in ProQR Therapeutics by 14.1% during the fourth quarter. Geode Capital Management LLC now owns 19,193 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 2,375 shares during the last quarter. FMR LLC lifted its stake in ProQR Therapeutics by 27.8% during the fourth quarter. FMR LLC now owns 1,081,366 shares of the biopharmaceutical company’s stock valued at $17,064,000 after purchasing an additional 235,053 shares during the last quarter. Millennium Management LLC acquired a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $1,428,000. Legal & General Group Plc acquired a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $1,057,000. Finally, Squarepoint Ops LLC acquired a new stake in ProQR Therapeutics during the fourth quarter valued at approximately $169,000. 59.69% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

See Also: Fundamental Analysis – How It Helps Investors

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

YENTEN  Price Down 25.7% This Week
YENTEN Price Down 25.7% This Week
Crowd Machine Trading 15.2% Higher  This Week
Crowd Machine Trading 15.2% Higher This Week
CSX Co.  Receives $79.58 Consensus PT from Analysts
CSX Co. Receives $79.58 Consensus PT from Analysts
Nectar  Price Hits $0.17 on Major Exchanges
Nectar Price Hits $0.17 on Major Exchanges
NCS Multistage Holdings Inc  Receives Average Rating of “Hold” from Brokerages
NCS Multistage Holdings Inc Receives Average Rating of “Hold” from Brokerages
MyBit  Trading Down 2.3% Over Last 7 Days
MyBit Trading Down 2.3% Over Last 7 Days


 
© 2006-2019 Zolmax.